Investigation of Natural WT1-specific and PRAME-specific Immunity in Ovarian Cancer
Completed
- Conditions
- ovarian cancer10038594
- Registration Number
- NL-OMON40116
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 96
Inclusion Criteria
- women newly diagnosed with epithelial ovarian cancer; prior to treatment or after neoadjuvant chemotherapy prior to cytoreductive surgery
- adequate venous access for blood collection
- 18 years of age or older
- informed consent
Exclusion Criteria
- previous or concurrent malignancies, other than basal or planocellular cancer of the skin
- concurrent immunosuppressive therapy, other than chemotherapy for ovarian cancer
- recurrent epithelial ovarian cancer
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Quantification and qualitative analysis of WT1-specific and PRAME-specific<br /><br>cellular and humoral immunity in patients with EOC during standard therapy. </p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>